Bcl-2 anticorps (N-Term)

N° du produit ABIN374455

Cet anticorps Chèvre Polyclonal détecte spécifiquement Bcl-2 dans WB et EIA. Il présente une réactivité avec des échantillons de Humain, Souris, Rat et Chien.

Aperçu rapide pour Bcl-2 anticorps (N-Term) (ABIN374455)

Antigène: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Reactivité: Humain, Souris, Rat, Chien

Hôte: Chèvre

Clonalité: Polyclonal

Conjugué: Cet anticorp Bcl-2 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Détail du produit anti-Bcl-2 anticorps

Épitope: N-Term

Séquence: AGRTGYDNRE IVMKYC

Specificité: This antibody is expected to recognise both reported isoforms (NP_000624, NP_000648) of BCL2.

Réactivité croisée (Details): Species reactivity (expected):Mouse, Rat, Canine.
Species reactivity (tested):Human.

Purification: Ammonium Sulphate Precipitation followed by Antigen Affinity Chromatography using the immunizing peptide.

Immunogène: Peptide with sequence from the N Terminus of the protein sequence according to NP_000624.2, NP_000648.2. Genename: BCL2

Information d'application

Indications d'application: Peptide ELISA: 1/32000. Western blot: 1 - 3 μg/mL.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Tris saline, pH 7.3 containing 0.02 % Sodium Azide as preservative and 0.5 % BSA as stabilizer.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur Bcl-2

Antigène: Bcl-2 (BCL2) (B-Cell CLL/lymphoma 2 (BCL2))

Autre désignation: Bcl-2

Sujet: BCL2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants (alpha and beta) produced by alternate splicing, differ in their C-terminal ends. BCL2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability. It appears to function in a feedback loop system with caspases. BCL2 inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF1). It can form homodimers, and heterodimers with BAX, BAD, BAK and BclX(L). Heterodimerization with BAX requires intact BH1 and BH2 domains, and is necessary for anti-apoptotic activity. Also interacts with APAF1, RAF1, TP53BP2, BBC3, BCL2L1 and BNIPL.Synonyms: Apoptosis regulator Bcl-2, B-Cell CLL/lymphoma 2, BCL2, Bcl-2 alpha

ID gène: 596, 9606

UniProt: P10415

Pathways: Signalisation MAPK, Signalisation PI3K-Akt, Apoptose, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling